Baystate Medical Center
- Type
- Teaching hospital
- Where
- SPRINGFIELD, MA
- Medicare CCN
- 220077
- Received
- $757,563 in 127 records, 2020 ($8,744 general, $748,819 research)
- Source
- CMS Open Payments search ↗
On this site
- Business registration: Baystate Medical Center, Inc. Fuzzy (name and state)
- Business registration: BAYSTATE MEDICAL CENTER INC Fuzzy (name and state)
- Business registration: BAYSTATE MEDICAL CENTER, INC. Fuzzy (name and state)
- Nonprofit contractor: BAYSTATE MEDICAL CENTER INC Fuzzy (name and state)
- Federal award recipient: BAYSTATE MEDICAL CENTER, INC. Fuzzy (name and state)
- Federal award recipient: BAYSTATE MEDICAL CENTER, INC. Fuzzy (name and state)
- Nonprofit: BAYSTATE MEDICAL CENTER INC Fuzzy (name and state)
- Patent assignee: BAYSTATE MEDICAL CENTER, INC. Fuzzy (name and state)
- Trademark owner: Baystate Medical Center, Inc. Fuzzy (name and state)
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2020 | General payment | 13 | $8,744 |
| 2020 | Research payment | 114 | $748,819 |
By company
| Company | Records | Amount | Years |
|---|---|---|---|
| Roche Products Limited | 24 | $392,065 | 2020 |
| Medtronic Vascular, Inc. | 14 | $68,689 | 2020 |
| GlaxoSmithKline, LLC. | 10 | $67,671 | 2020 |
| Genentech, Inc. | 3 | $65,333 | 2020 |
| Hoffmann-La Roche Limited | 2 | $29,570 | 2020 |
| Amgen Inc. | 4 | $20,583 | 2020 |
| BIOTRONIK INC. | 16 | $16,411 | 2020 |
| Chiesi USA, Inc. | 6 | $14,234 | 2020 |
| GENZYME CORPORATION | 5 | $11,895 | 2020 |
| Celgene Corporation | 1 | $11,500 | 2020 |
| Gilead Sciences, Inc. | 4 | $8,890 | 2020 |
| ViiV Healthcare Company | 3 | $8,451 | 2020 |
| JAZZ PHARMACEUTICALS INC. | 4 | $8,425 | 2020 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $6,730 | 2020 |
| AstraZeneca Pharmaceuticals LP | 5 | $6,273 | 2020 |
| Endologix LLC | 2 | $4,546 | 2020 |
| Daiichi Sankyo Inc. | 5 | $4,498 | 2020 |
| Stryker Corporation | 1 | $2,909 | 2020 |
| Abbott Laboratories | 5 | $2,523 | 2020 |
| SEAGEN INC. | 1 | $1,375 | 2020 |
| Amicus Therapeutics, Inc. | 1 | $1,300 | 2020 |
| Janssen Pharmaceuticals, Inc | 1 | $1,000 | 2020 |
| GenMark Diagnostics, Inc. | 1 | $975 | 2020 |
| bioMerieux Inc | 2 | $750 | 2020 |
| Siemens Medical Solutions USA, Inc. | 1 | $669 | 2020 |
| Helena Laboratories Corporation | 3 | $225 | 2020 |
| Masimo Corporation | 1 | $67 | 2020 |
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 114 | $748,819 |
| Space rental or facility fees (teaching hospital only) | 4 | $3,999 |
| Gift | 3 | $3,659 |
| Charitable Contribution | 1 | $669 |
| Entertainment | 3 | $225 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 1 | $123 |
| Education | 1 | $67 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2020-12-31 | Stryker Corporation | $2,909 | Gift | Cash or cash equivalent | NONE Device, NONE | 2020 | |
| 2020-12-31 | Siemens Medical Solutions USA, Inc. | $669 | Charitable Contribution | In-kind items and services | 2020 | ||
| 2020-12-31 | bioMerieux Inc | $375 | Gift | In-kind items and services | ASTUTE METER Device, Diagnostics | 2020 | |
| 2020-12-31 | bioMerieux Inc | $375 | Gift | In-kind items and services | ASTUTE METER Device, Diagnostics | 2020 | |
| 2020-12-31 | Masimo Corporation | $67 | Education | In-kind items and services | EMMA and ISA Device, Devices | 2020 | |
| 2020-12-31 | AstraZeneca Pharmaceuticals LP | $1 | Research payment | In-kind items and services | LYNPARZA Drug, Oncology | This is a non randomized open label study to assess olaparib tablets as a treatment for subjects with different homologo | 2020 |
| 2020-12-24 | Amgen Inc. | $3,000 | Research payment | Cash or cash equivalent | Repatha Biological, Cardiology | VESALIUS - CV | 2020 |
| 2020-12-15 | Abbott Laboratories | $325 | Research payment | Cash or cash equivalent | Xience Sierra Coronary Stent System Device, Vascular | XIENCE 90: A Safety Evaluation of 3-month DAPT After XIENCE Implantation for HBR Patients | 2020 |
| 2020-12-14 | GlaxoSmithKline, LLC. | $14,022 | Research payment | Cash or cash equivalent | A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERA | 2020 | |
| 2020-12-08 | BIOTRONIK INC. | $360 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-VII | 2020 |
| 2020-12-08 | BIOTRONIK INC. | $78 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-VII | 2020 |
| 2020-12-08 | BIOTRONIK INC. | $78 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-VII | 2020 |
| 2020-12-08 | BIOTRONIK INC. | $26 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-VII | 2020 |
| 2020-12-03 | Hoffmann-La Roche Limited | $850 | Research payment | Cash or cash equivalent | Actemra Biological, Immunology | SAFETY EFFICACY OF A COMBINATION OF REMDESIVIR TOCILIZUMAB IN SEVERE COVID 19 PNEUMONIA | 2020 |
| 2020-12-01 | Roche Products Limited | $19,684 | Research payment | Cash or cash equivalent | Actemra Biological, Immunology | COVACTA ACTEMRA COVID 19 PNEUMONIA STUDY | 2020 |
| 2020-12-01 | Roche Products Limited | $4,512 | Research payment | Cash or cash equivalent | Actemra Biological, Immunology | COVACTA ACTEMRA COVID 19 PNEUMONIA STUDY | 2020 |
| 2020-12-01 | Roche Products Limited | $1,559 | Research payment | Cash or cash equivalent | Actemra Biological, Immunology | COVACTA ACTEMRA COVID 19 PNEUMONIA STUDY | 2020 |
| 2020-11-23 | GlaxoSmithKline, LLC. | $3,747 | Research payment | Cash or cash equivalent | A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERA | 2020 | |
| 2020-11-18 | Gilead Sciences, Inc. | $1,764 | Research payment | Cash or cash equivalent | Biktarvy Drug, HIV | A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir Alafena | 2020 |
| 2020-11-17 | Roche Products Limited | $250 | Research payment | Cash or cash equivalent | Actemra Biological, Immunology | COVACTA ACTEMRA COVID 19 PNEUMONIA STUDY | 2020 |
| 2020-11-11 | Medtronic Vascular, Inc. | $2,068 | Research payment | Cash or cash equivalent | TAVR Low Risk CAS | 2020 | |
| 2020-11-11 | Medtronic Vascular, Inc. | $2,068 | Research payment | Cash or cash equivalent | TAVR Low Risk CAS | 2020 | |
| 2020-11-10 | Abbott Laboratories | $650 | Research payment | Cash or cash equivalent | Xience Sierra Coronary Stent System Device, Vascular | XIENCE 90: A Safety Evaluation of 3-month DAPT After XIENCE Implantation for HBR Patients | 2020 |
| 2020-11-09 | GENZYME CORPORATION | $2,372 | Research payment | Cash or cash equivalent | Fabry LSD Data Registry | 2020 | |
| 2020-11-03 | Amicus Therapeutics, Inc. | $1,300 | Research payment | Cash or cash equivalent | PROPEL Study - A Study Comparing ATB200/AT2221 With Alglucosidase/Placebo in Adult Subjects With LOPD | 2020 | |
| 2020-11-03 | BIOTRONIK INC. | $490 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-VII | 2020 |
| 2020-11-03 | BIOTRONIK INC. | $360 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-VII | 2020 |
| 2020-11-03 | BIOTRONIK INC. | $193 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-VII | 2020 |
| 2020-11-03 | BIOTRONIK INC. | $104 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-VII | 2020 |
| 2020-11-03 | BIOTRONIK INC. | $78 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-VII | 2020 |
| 2020-11-03 | BIOTRONIK INC. | $78 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-VII | 2020 |
| 2020-11-03 | BIOTRONIK INC. | $26 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-VII | 2020 |
| 2020-10-29 | Medtronic Vascular, Inc. | $14,550 | Research payment | Cash or cash equivalent | CoreValve Evolut Device, Transcatheter Valve Systems | TAVR Low Risk | 2020 |
| 2020-10-29 | Medtronic Vascular, Inc. | $14,550 | Research payment | Cash or cash equivalent | CoreValve Evolut Device, Transcatheter Valve Systems | TAVR Low Risk | 2020 |
| 2020-10-29 | Abbott Laboratories | $123 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2020 | ||
| 2020-10-26 | Genentech, Inc. | $9,251 | Research payment | Cash or cash equivalent | Avastin Biological, BioOncology | A PHASE III MULTICENTER RANDOMIZED PLACEBO CONTROLLED STUDY OF ATEZOLIZUMAB VERSUS PLACEBO IN COM | 2020 |
| 2020-10-23 | Amgen Inc. | $6,250 | Research payment | Cash or cash equivalent | Repatha Biological, Cardiology | VESALIUS - CV | 2020 |
| 2020-10-19 | GlaxoSmithKline, LLC. | $5,792 | Research payment | Cash or cash equivalent | A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERA | 2020 | |
| 2020-10-15 | Roche Products Limited | $6,529 | Research payment | Cash or cash equivalent | Actemra Biological, Immunology | COVACTA ACTEMRA COVID 19 PNEUMONIA STUDY | 2020 |
| 2020-10-15 | Roche Products Limited | $5,947 | Research payment | Cash or cash equivalent | Actemra Biological, Immunology | COVACTA ACTEMRA COVID 19 PNEUMONIA STUDY | 2020 |
| 2020-10-15 | Roche Products Limited | $700 | Research payment | Cash or cash equivalent | Actemra Biological, Immunology | COVACTA ACTEMRA COVID 19 PNEUMONIA STUDY | 2020 |
| 2020-10-15 | Roche Products Limited | $350 | Research payment | Cash or cash equivalent | Actemra Biological, Immunology | COVACTA ACTEMRA COVID 19 PNEUMONIA STUDY | 2020 |
| 2020-10-15 | Roche Products Limited | $250 | Research payment | Cash or cash equivalent | Actemra Biological, Immunology | COVACTA ACTEMRA COVID 19 PNEUMONIA STUDY | 2020 |
| 2020-10-13 | Hoffmann-La Roche Limited | $28,720 | Research payment | Cash or cash equivalent | Actemra Biological, Immunology | SAFETY EFFICACY OF A COMBINATION OF REMDESIVIR TOCILIZUMAB IN SEVERE COVID 19 PNEUMONIA | 2020 |
| 2020-10-07 | AstraZeneca Pharmaceuticals LP | $1,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | BRILINTA Drug, Cardiovascular and Metabolism | 2020 | |
| 2020-10-03 | JAZZ PHARMACEUTICALS INC. | $5,625 | Research payment | Cash or cash equivalent | XYWAV Drug, NEUROLOGY | A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER STUDY OF THE EFFICACY AND SAFETY OF JZP-258 IN TH | 2020 |
| 2020-10-01 | Chiesi USA, Inc. | $1,500 | Research payment | Cash or cash equivalent | PORACTANT ALFA / CUROSURF Drug, NEONATOLOGY | CCD-5633AA1-02 | 2020 |
| 2020-09-23 | Janssen Pharmaceuticals, Inc | $1,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | XARELTO Drug, Cardiovascular & Metabolism | 2020 | |
| 2020-09-17 | Chiesi USA, Inc. | $1,096 | Research payment | Cash or cash equivalent | PORACTANT ALFA / CUROSURF Drug, NEONATOLOGY | CCD-5633AA1-02 | 2020 |
| 2020-09-16 | Amgen Inc. | $7,683 | Research payment | In-kind items and services | Repatha Biological, Cardiology | VESALIUS - CV | 2020 |
| 2020-09-14 | GlaxoSmithKline, LLC. | $369 | Research payment | Cash or cash equivalent | A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERA | 2020 | |
| 2020-09-09 | BIOTRONIK INC. | $490 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-VII | 2020 |
| 2020-09-09 | BIOTRONIK INC. | $193 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-VII | 2020 |
| 2020-09-09 | BIOTRONIK INC. | $104 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-VII | 2020 |
| 2020-09-06 | JAZZ PHARMACEUTICALS INC. | $1,300 | Research payment | Cash or cash equivalent | XYWAV Drug, NEUROLOGY | A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER STUDY OF THE EFFICACY AND SAFETY OF JZP-258 IN TH | 2020 |
| 2020-09-06 | JAZZ PHARMACEUTICALS INC. | $1,000 | Research payment | Cash or cash equivalent | XYWAV Drug, NEUROLOGY | A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER STUDY OF THE EFFICACY AND SAFETY OF JZP-258 IN TH | 2020 |
| 2020-09-06 | JAZZ PHARMACEUTICALS INC. | $500 | Research payment | Cash or cash equivalent | XYWAV Drug, NEUROLOGY | A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER STUDY OF THE EFFICACY AND SAFETY OF JZP-258 IN TH | 2020 |
| 2020-09-01 | Genentech, Inc. | $12,397 | Research payment | Cash or cash equivalent | Avastin Biological, BioOncology | A PHASE III MULTICENTER RANDOMIZED PLACEBO CONTROLLED STUDY OF ATEZOLIZUMAB VERSUS PLACEBO IN COM | 2020 |
| 2020-09-01 | AstraZeneca Pharmaceuticals LP | $1,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | BRILINTA Drug, Cardiovascular and Metabolism | 2020 | |
| 2020-08-20 | Roche Products Limited | $3,470 | Research payment | Cash or cash equivalent | Actemra Biological, Immunology | COVACTA ACTEMRA COVID 19 PNEUMONIA STUDY | 2020 |
| 2020-08-20 | Roche Products Limited | $3,143 | Research payment | Cash or cash equivalent | Actemra Biological, Immunology | COVACTA ACTEMRA COVID 19 PNEUMONIA STUDY | 2020 |
| 2020-08-19 | Gilead Sciences, Inc. | $1,676 | Research payment | Cash or cash equivalent | Biktarvy Drug, HIV | A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir Alafena | 2020 |
| 2020-08-18 | Roche Products Limited | $250 | Research payment | Cash or cash equivalent | Actemra Biological, Immunology | COVACTA ACTEMRA COVID 19 PNEUMONIA STUDY | 2020 |
| 2020-08-18 | Roche Products Limited | $250 | Research payment | Cash or cash equivalent | Actemra Biological, Immunology | COVACTA ACTEMRA COVID 19 PNEUMONIA STUDY | 2020 |
| 2020-08-18 | Roche Products Limited | $200 | Research payment | Cash or cash equivalent | Actemra Biological, Immunology | COVACTA ACTEMRA COVID 19 PNEUMONIA STUDY | 2020 |
| 2020-08-18 | Roche Products Limited | $100 | Research payment | Cash or cash equivalent | Actemra Biological, Immunology | COVACTA ACTEMRA COVID 19 PNEUMONIA STUDY | 2020 |
| 2020-08-17 | GlaxoSmithKline, LLC. | $1,737 | Research payment | Cash or cash equivalent | A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERA | 2020 | |
| 2020-08-11 | Celgene Corporation | $11,500 | Research payment | Cash or cash equivalent | Revlimid Drug, Hematology | Celgene - Connect MM | 2020 |
| 2020-08-11 | Roche Products Limited | $850 | Research payment | Cash or cash equivalent | Actemra Biological, Immunology | COVACTA ACTEMRA COVID 19 PNEUMONIA STUDY | 2020 |
| 2020-08-11 | Roche Products Limited | $650 | Research payment | Cash or cash equivalent | Actemra Biological, Immunology | COVACTA ACTEMRA COVID 19 PNEUMONIA STUDY | 2020 |
| 2020-08-11 | BIOTRONIK INC. | $250 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-VII | 2020 |
| 2020-08-06 | Endologix LLC | $2,806 | Research payment | Cash or cash equivalent | NELLIX EVAS CONTINUED ACCESS | 2020 | |
| 2020-08-06 | Endologix LLC | $1,740 | Research payment | Cash or cash equivalent | NELLIX EVAS CONTINUED ACCESS | 2020 | |
| 2020-08-03 | Medtronic Vascular, Inc. | $3,572 | Research payment | Cash or cash equivalent | TAVR Low Risk CAS | 2020 | |
| 2020-08-03 | Medtronic Vascular, Inc. | $3,572 | Research payment | Cash or cash equivalent | TAVR Low Risk CAS | 2020 | |
| 2020-07-28 | Roche Products Limited | $311,021 | Research payment | Cash or cash equivalent | Actemra Biological, Immunology | COVACTA ACTEMRA COVID 19 PNEUMONIA STUDY | 2020 |
| 2020-07-23 | Amgen Inc. | $3,650 | Research payment | Cash or cash equivalent | Repatha Biological, Cardiology | VESALIUS - CV | 2020 |
| 2020-07-20 | GlaxoSmithKline, LLC. | $3,523 | Research payment | Cash or cash equivalent | A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERA | 2020 | |
| 2020-07-07 | BIOTRONIK INC. | $13,500 | Research payment | Cash or cash equivalent | Orsiro Device, Cardiology/Vascular Diseases | BIOFLOW-VII | 2020 |
| 2020-07-07 | Roche Products Limited | $650 | Research payment | Cash or cash equivalent | Actemra Biological, Immunology | COVACTA ACTEMRA COVID 19 PNEUMONIA STUDY | 2020 |
| 2020-07-06 | GlaxoSmithKline, LLC. | $2,022 | Research payment | Cash or cash equivalent | A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERA | 2020 | |
| 2020-06-29 | SEAGEN INC. | $1,375 | Research payment | Cash or cash equivalent | A Single Arm, Multicenter, International Trial of Tisotumab Vedotin (HuMax-TF-ADC) in Previously Treated, Recurrent or M | 2020 | |
| 2020-06-17 | Gilead Sciences, Inc. | $3,774 | Research payment | Cash or cash equivalent | Biktarvy Drug, HIV | A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir Alafena | 2020 |
| 2020-06-16 | Abbott Laboratories | $775 | Research payment | Cash or cash equivalent | Xience Sierra Coronary Stent System Device, Vascular | XIENCE 90: A Safety Evaluation of 3-month DAPT After XIENCE Implantation for HBR Patients | 2020 |
| 2020-06-04 | Roche Products Limited | $6,800 | Research payment | Cash or cash equivalent | Actemra Biological, Immunology | COVACTA ACTEMRA COVID 19 PNEUMONIA STUDY | 2020 |
| 2020-06-03 | AstraZeneca Pharmaceuticals LP | $999 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | BYDUREON Drug, Cardiovascular and Metabolism | 2020 | |
| 2020-05-28 | Boehringer Ingelheim Pharmaceuticals, Inc. | $4,130 | Research payment | Cash or cash equivalent | OFEV Drug, RESPIRATORY | Pulmonary Rehabilitation and Nintedanib in IPF | 2020 |
| 2020-05-26 | GlaxoSmithKline, LLC. | $2,175 | Research payment | Cash or cash equivalent | A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERA | 2020 | |
| 2020-05-26 | Roche Products Limited | $1,700 | Research payment | Cash or cash equivalent | Actemra Biological, Immunology | COVACTA ACTEMRA COVID 19 PNEUMONIA STUDY | 2020 |
| 2020-05-20 | Genentech, Inc. | $43,685 | Research payment | Cash or cash equivalent | Avastin Biological, BioOncology | A PHASE III MULTICENTER RANDOMIZED PLACEBO CONTROLLED STUDY OF ATEZOLIZUMAB VERSUS PLACEBO IN COM | 2020 |
| 2020-05-13 | Medtronic Vascular, Inc. | $2,858 | Research payment | Cash or cash equivalent | TAVR Low Risk CAS | 2020 | |
| 2020-05-13 | Medtronic Vascular, Inc. | $2,858 | Research payment | Cash or cash equivalent | TAVR Low Risk CAS | 2020 | |
| 2020-05-12 | Roche Products Limited | $17,850 | Research payment | Cash or cash equivalent | Actemra Biological, Immunology | COVACTA ACTEMRA COVID 19 PNEUMONIA STUDY | 2020 |
| 2020-05-12 | Roche Products Limited | $3,400 | Research payment | Cash or cash equivalent | Actemra Biological, Immunology | COVACTA ACTEMRA COVID 19 PNEUMONIA STUDY | 2020 |
| 2020-05-07 | Chiesi USA, Inc. | $350 | Research payment | Cash or cash equivalent | PORACTANT ALFA / CUROSURF Drug, NEONATOLOGY | CCD-5633AA1-02 | 2020 |
| 2020-05-07 | Chiesi USA, Inc. | $350 | Research payment | Cash or cash equivalent | PORACTANT ALFA / CUROSURF Drug, NEONATOLOGY | CCD-5633AA1-02 | 2020 |
| 2020-05-05 | Roche Products Limited | $1,950 | Research payment | Cash or cash equivalent | Actemra Biological, Immunology | COVACTA ACTEMRA COVID 19 PNEUMONIA STUDY | 2020 |
| 2020-05-04 | Medtronic Vascular, Inc. | $4,456 | Research payment | Cash or cash equivalent | CoreValve Evolut Device, Transcatheter Valve Systems | TAVR Low Risk | 2020 |
| 2020-05-04 | Medtronic Vascular, Inc. | $4,456 | Research payment | Cash or cash equivalent | CoreValve Evolut Device, Transcatheter Valve Systems | TAVR Low Risk | 2020 |
| 2020-05-04 | GENZYME CORPORATION | $2,892 | Research payment | Cash or cash equivalent | Pompe LSD Data Registry | 2020 | |
| 2020-05-04 | GENZYME CORPORATION | $2,015 | Research payment | Cash or cash equivalent | Fabry LSD Data Registry | 2020 | |
| 2020-05-01 | ViiV Healthcare Company | $767 | Research payment | Cash or cash equivalent | TIVICAY Drug, HIV | A PHASE III, RANDOMISED, DOUBLE-BLIND, MULTICENTRE, PARALLEL-GROUP, NO | 2020 |
| 2020-04-27 | GlaxoSmithKline, LLC. | $5,450 | Research payment | Cash or cash equivalent | A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERA | 2020 | |
| 2020-04-27 | Chiesi USA, Inc. | $3,288 | Research payment | Cash or cash equivalent | PORACTANT ALFA / CUROSURF Drug, NEONATOLOGY | CCD-5633AA1-02 | 2020 |
| 2020-04-06 | GlaxoSmithKline, LLC. | $28,831 | Research payment | Cash or cash equivalent | A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERA | 2020 | |
| 2020-03-18 | Gilead Sciences, Inc. | $1,676 | Research payment | Cash or cash equivalent | Biktarvy Drug, HIV | A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir Alafena | 2020 |
| 2020-03-03 | GENZYME CORPORATION | $3,835 | Research payment | Cash or cash equivalent | Fabry LSD Data Registry | 2020 | |
| 2020-03-03 | GENZYME CORPORATION | $780 | Research payment | Cash or cash equivalent | Pompe LSD Data Registry | 2020 | |
| 2020-03-02 | Boehringer Ingelheim Pharmaceuticals, Inc. | $2,600 | Research payment | Cash or cash equivalent | OFEV Drug, RESPIRATORY | Pulmonary Rehabilitation and Nintedanib in IPF | 2020 |
| 2020-02-19 | Daiichi Sankyo Inc. | $1,300 | Research payment | Cash or cash equivalent | Savaysa Drug, Thrombosis | ENVISAGE | 2020 |
| 2020-02-19 | Daiichi Sankyo Inc. | $1,300 | Research payment | Cash or cash equivalent | Savaysa Drug, Thrombosis | ENVISAGE | 2020 |
| 2020-02-19 | Daiichi Sankyo Inc. | $689 | Research payment | Cash or cash equivalent | Savaysa Drug, Thrombosis | ENVISAGE | 2020 |
| 2020-02-19 | Daiichi Sankyo Inc. | $689 | Research payment | Cash or cash equivalent | Savaysa Drug, Thrombosis | ENVISAGE | 2020 |
| 2020-02-19 | Daiichi Sankyo Inc. | $520 | Research payment | Cash or cash equivalent | Savaysa Drug, Thrombosis | ENVISAGE | 2020 |
| 2020-02-03 | ViiV Healthcare Company | $6,783 | Research payment | Cash or cash equivalent | TIVICAY Drug, HIV | A PHASE III, RANDOMISED, DOUBLE-BLIND, MULTICENTRE, PARALLEL-GROUP, NO | 2020 |
| 2020-01-31 | Helena Laboratories Corporation | $3 | Entertainment | In-kind items and services | 2020 | ||
| 2020-01-30 | Helena Laboratories Corporation | $12 | Entertainment | In-kind items and services | 2020 | ||
| 2020-01-27 | Chiesi USA, Inc. | $7,650 | Research payment | Cash or cash equivalent | PORACTANT ALFA / CUROSURF Drug, NEONATOLOGY | CCD-5633AA1-02 | 2020 |
| 2020-01-17 | Abbott Laboratories | $650 | Research payment | Cash or cash equivalent | Xience Sierra Coronary Stent System Device, Vascular | XIENCE 90: A Safety Evaluation of 3-month DAPT After XIENCE Implantation for HBR Patients | 2020 |
| 2020-01-16 | Medtronic Vascular, Inc. | $6,366 | Research payment | Cash or cash equivalent | CoreValve Evolut Device, Transcatheter Valve Systems | TAVR Low Risk | 2020 |
| 2020-01-16 | Medtronic Vascular, Inc. | $6,366 | Research payment | Cash or cash equivalent | CoreValve Evolut Device, Transcatheter Valve Systems | TAVR Low Risk | 2020 |
| 2020-01-16 | Medtronic Vascular, Inc. | $473 | Research payment | Cash or cash equivalent | TAVR Low Risk CAS | 2020 | |
| 2020-01-16 | Medtronic Vascular, Inc. | $473 | Research payment | Cash or cash equivalent | TAVR Low Risk CAS | 2020 | |
| 2020-01-15 | Helena Laboratories Corporation | $210 | Entertainment | In-kind items and services | 2020 | ||
| 2020-01-09 | AstraZeneca Pharmaceuticals LP | $3,272 | Research payment | Cash or cash equivalent | LYNPARZA Drug, Oncology | This is a non randomized open label study to assess olaparib tablets as a treatment for subjects with different homologo | 2020 |
| 2020-01-08 | ViiV Healthcare Company | $900 | Research payment | Cash or cash equivalent | TIVICAY Drug, HIV | A PHASE III, RANDOMISED, DOUBLE-BLIND, MULTICENTRE, PARALLEL-GROUP, NO | 2020 |
| 2020-01-02 | GenMark Diagnostics, Inc. | $975 | Research payment | Cash or cash equivalent | ePlex Device, Devices | FM GenMark 16069 | 2020 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Springfield, MA, county Hampden County, MA, state Massachusetts; placed by its city name.
| Measure | Place (city or town) Springfield, MA | County Hampden County, MA | State Massachusetts |
|---|---|---|---|
| Population B01003 | 154,749 | 462,815 | 7,044,056 |
| Population, 2020 census P1 | 155,929 | 465,825 | 7,029,917 |
| Median age B01002 | 33.7 | 40.0 | 40.0 |
| Under 18 B01001 | 24.2% | 20.9% | 19.4% |
| 65 and over B01001 | 13.2% | 18.3% | 17.9% |
| Households B11001 | 57,772 | 184,471 | 2,785,042 |
| Foreign born B05002 | 10.5% | 9.4% | 18.0% |
| Median household income B19013 | $52,656 | $71,306 | $103,960 |
| Median family income B19113 | $66,045 | $91,397 | $131,675 |
| Per capita income B19301 | $27,337 | $38,219 | $57,897 |
| Poverty rate B17001 | 25.8% | 16.3% | 10.0% |
| Unemployment rate B23025 | 8.7% | 6.0% | 5.2% |
| Civilian labor force B23025 | 69,390 | 226,771 | 3,911,446 |
| Mean commute (minutes) B08013 | 20.2 | 22.7 | 29.1 |
| Bachelor's degree or higher B15003 | 20.5% | 29.3% | 47.3% |
| Housing units B25001 | 62,217 | 197,591 | 3,030,406 |
| Owner-occupied B25003 | 49.6% | 62.2% | 62.5% |
| Renters B25003 | 50.4% | 37.8% | 37.5% |
| Median home value B25077 | $245,000 | $298,800 | $562,100 |
| Median gross rent B25064 | $1,144 | $1,136 | $1,762 |
| White, not Hispanic B03002 | 27.8% | 59.3% | 66.6% |
| Black B03002 | 17.5% | 7.6% | 6.4% |
| Hispanic or Latino B03002 | 48.6% | 27.0% | 13.3% |
| Asian B03002 | 2.7% | 2.5% | 7.3% |
| American Indian and Alaska Native B03002 | 0.1% | 0.0% | 0.1% |
Economy now FRED unemployment 4.3% in Sep 2026 (4.6% a year earlier); per capita personal income $98,700 in 2025, up 27% in five years (+2.3% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Springfield, MA.
Comments